Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Vivoryon Therapeutics N.V.
  6. News
  7. Summary
    VVY   NL00150002Q7

VIVORYON THERAPEUTICS N.V.

(VVY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vivoryon Therapeutics N : Presentation

09/21/2021 | 09:12am EDT

HALF YEAR 2020 RESULTS WEBCAST AND CONFERENCE CALL

September 21, 2021

|Vivoryon Therapeutics N.V.

IMPORTANT NOTICE AND DISCLAIMER

This Presentation has been prepared and issued by Vivoryon Therapeutics N.V. (the "Company") and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts and nothing in this Presentation is or should be relied on as a promise or representation as to the future.

All statements other than statements of historical fact included in this Presentation are or may be deemed to be forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Company, estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This Presentation does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company.

This Presentation, including any forward-looking statements, speaks only as of the date of this Presentation. The Company does not assume any obligation to update any information or forward looking statements contained herein, save for any information required to be disclosed by law.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness, and any reliance a recipient places on them will be at the recipient's sole risk. No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its respective directors, officers, employees, affiliates, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any of them for any such information or opinions. The information set out herein may be subject without notice to updating, revision, verification and amendment which may materially change such information.

This Presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

2

  • Vivoryon Therapeutics N.V. H1 2021 - September 21, 2021

VIVORYON THERAPEUTICS

Overview

Enzyme inhibition for targeted intervention: Modulating the activity of proteins altered in disease settings

Lead product candidate varoglutamstat in AD: Phase 2a evidence of disease-modifying activity

Statistically significant improvement in working memory after 3-months treatment Upstream intervention with dual MoA: Targeting the QPCT/L and CCL2 pathways

Targets all three major hallmarks of AD: Abeta aggregation, neuroinflammation and tau pathology, as well as synaptic function

Ongoing Phase 2b program in AD designed to provide clear path to regulatory approval1

Oral small molecule: Good blood-brain-barrier penetration, intracellular activity, attractive COGS

Large pharma partnership deals: Simcere (QPCT/L in AD; Greater China regional partnership worth up to US$ 565 M), OSI/Astellas (DPP4), AstraZeneca (CDK9)

Follow-upprograms in oncology, inflammatory diseases/NASH and AKI/fibrosis

Strong IP including composition of matter coverage beyond 2035

AD: Alzheimer's disease; CCL2: chemokine (C-C motif) ligand 2; CDK9: Cyclin-dependent kinase 9; COGs: cost of goods; DPP4: dipeptidyl peptidase-4;

3

© Vivoryon Therapeutics N.V. H1 2021 - September 21, 2021

QPCT/L: glutaminyl cyclase and glutaminyl cyclase-like protein; 1Cummings, Feldman and Scheltens, 2019

KEY UPDATES

  • US Phase 2a/b VIVA-MIND study for varoglutamstat in patients with early AD being initiated as planned, with the first site now approved to initiate screening
  • Strategic regional licensing partnership with Simcere to develop and commercialize N3pE amyloid- targeting medicines to treat AD in Greater China; Vivoryon to receive combined upfront and milestone payments of up to US$565 M plus double-digit royalties on sales
  • Enrollment into European Phase 2b VIVIAD study in patients with mild cognitive impairment and mild AD on track with additional study centers opened to balance effects of COVID-19 related patient and staff protection policies implemented at German study sites; study details recently published as Vijverberg et al., Alzheimer's Research & Therapy (2021) 13:142
  • Significant expansion of patent portfolio with a total of 14 additional patents granted for Vivoryon's small molecule inhibitors and antibody-based medicines in development to treat AD and other diseases with exceptionally high medical need
  • Florian Schmid joined Vivoryon as Chief Financial Officer
  • AGM: shareholders approved all resolutions with large majority

4

  • Vivoryon Therapeutics N.V. H1 2021 - September 21, 2021

THERAPEUTIC INTERVENTIONS IN AD

Varoglutamstat Inhibits Formation of Toxic Abeta Species Upstream of Other Approaches

ROLE OF QPCT/L IN AD PATHOLOGY

VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS

Increased activity of glutaminyl cyclase (QPCT) is associated with AD pathology1

QPCT catalyzes formation of neurotoxic N3pE amyloid by cyclization of N-terminal glutamate on Abeta2

N3pE amyloid correlates with QPCT expression and MMSE status in AD patients and is not found in healthy individuals3

N3pE amyloid is a validated target: Phase 2 data from VVY's small molecule varoglutamstat and Lilly's mAb donanemab

Targeting QPCTL:

Varoglutamstat

Lecanemab Donanemab

Aducanumab

Gantenerumab

Abeta

CCL2

QPCT/L

N3pE

pE-CCL2

upregulated in AD

catalyze conversion

elicit downstream pathology

Inhibits neuroinflammation by modulating CCL2 activity

Increased levels of QPCTL and high pE-CCL2 levels

correlate strongly with low MMSE scores4

Abeta

Synaptic impairment

Tau pathology Neuroinflammation

pathology

1Gunn et al., J.Neurochem 2021; 2 Schilling et al., Nat. Med. 2008;

3Morawski et. al., JAD 2014; Nussbaum et al., Nature 2012; 4Hartlage-Rübsamen et al., Acta Neuropathol, 2015

5

  • Vivoryon Therapeutics N.V. H1 2021 - September 21, 2021

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Vivoryon Therapeutics NV published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 13:11:05 UTC.


ę Publicnow 2021
All news about VIVORYON THERAPEUTICS N.V.
10/18VIVORYON THERAPEUTICS N : Vivoryon Therapeutics Provides Update on Business and Progress o..
PU
10/18VIVORYON THERAPEUTICS N : Continues To Enroll Patients In Mid-Stage Studies Of Alzheimer's..
MT
10/18VIVORYON THERAPEUTICS N.V. : Vivoryon Therapeutics Provides Update on Business and Progres..
EQ
10/18PRESS RELEASE : Vivoryon Therapeutics N.V.: -2-
DJ
10/18PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Busin..
DJ
10/18Vivoryon Therapeutics N.V Provides Update on Business and Progress of Varoglutamstat Cl..
CI
09/21VIVORYON THERAPEUTICS N : Presentation
PU
09/21VIVORYON THERAPEUTICS N : Reports H1 2021 Financial Results and Operational Progress
PU
09/21VIVORYON THERAPEUTICS N : Interim Financial Statements June 30, 2021
PU
09/21VIVORYON THERAPEUTICS N : Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and..
PU
More news
Financials
Sales 2021 - - -
Net income 2021 -15,9 M -18,5 M -18,5 M
Net cash 2021 8,23 M 9,55 M 9,55 M
P/E ratio 2021 -23,2x
Yield 2021 -
Capitalization 369 M 428 M 429 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 18
Free-Float 70,7%
Chart VIVORYON THERAPEUTICS N.V.
Duration : Period :
Vivoryon Therapeutics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIVORYON THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 18,45 €
Average target price 40,50 €
Spread / Average Target 120%
EPS Revisions
Managers and Directors
Ulrich Dauer Chief Executive Officer & Executive Director
Florian Schmid Chief Financial Officer & Executive Director
Erich Maximilian Platzer Non-Executive Chairman
Frank T. Weber Chief Medical Officer
J÷rg Neermann Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
VIVORYON THERAPEUTICS N.V.104.73%429
MODERNA, INC.226.29%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.41.93%48 923
SEAGEN INC.-0.30%32 330
CELLTRION, INC.-39.00%26 036